⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614887 | 0.91 | — | — | |
| SCHEMBL18366406 | 0.91 | — | — | |
| SCHEMBL12542094 | 0.89 | ALDH1A1 (0.31) | — | |
| SCHEMBL24373097 | 0.89 | — | — | |
| SCHEMBL16336025 | 0.85 | NEK2 (0.31) | — | |
| SCHEMBL27096692 | 0.81 | — | — | |
| SCHEMBL4693969 | 0.79 | TRIM24 (0.32) | — | |
| SCHEMBL28272317 | 0.79 | TRIM24 (0.32) | — | |
| SCHEMBL14966409 | 0.78 | TRIM24 (0.31) | — | |
| SCHEMBL140593 | 0.78 | MGLL (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617783-B2 | Heterocyclic GLP-1R agonists | BIOMEA FUSION, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250304572-A1 | HETEROCYCLIC GLP-1R AGONISTS | BIOMEA FUSION, INC. | 2025-10-02 | — | — | US | disclosed |
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025137640-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-115279771-B | MAP4K1 inhibitors | 缆图药品公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250074875-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2025-03-06 | — | — | US | disclosed |
| US-12122750-B2 | AT2R antagonists and uses thereof | ELI LILLY AND COMPANY (US) | 2024-10-22 | — | — | US | disclosed |
| US-12042495-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-23 | — | — | US | disclosed |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| WO-2014110688-A1 | THIOPHENE- SUB STITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014065791-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-01 | — | — | WO | disclosed |
| US-20130121957-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-16 | — | — | US | disclosed |
| US-20130121957-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-16 | — | — | US | disclosed |
| EP-2590968-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | Novartis AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012154777-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120195857-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-02 | — | — | US | disclosed |
| US-20120195857-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-02 | — | — | US | disclosed |
| WO-2012021591-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |